# rxepitalon.com # Epitalon (Epithalon): The Khavinson Pineal Tetrapeptide AEDG — A Literature Digest > Epitalon is the synthetic AEDG tetrapeptide designed by Vladimir Khavinson's St. Petersburg group from the bovine pineal extract Epithalamin. A textile-layered editorial digest of the telomerase, melatonin, and rodent-lifespan record. A sober editorial digest of twenty-five years of in vitro telomerase work, rodent geroprotection studies, and small Russian human cohorts — with every quantitative claim cited and every literature limit named. ## What Epitalon is, in one paragraph Epitalon is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly — the AEDG peptide — designed in the late 1980s and 1990s by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology [1]. The molecule was reverse-engineered from the amino-acid profile of Epithalamin, a crude polypeptide extract of the bovine pineal gland that the Khavinson program had been studying for two decades [1][14]. Its molecular formula is `C14H22N4O9`, its molar mass 390.35 g/mol, and the TFA salt commonly used in research carries the CAS registry number 307297-39-8 [15]. The compound is also catalogued under the spellings [Epithalon (with an h)](/epithalon) and Epithalone — transliterations from the Russian — and a tight definitional page on [what is Epitalon](/what-is-epitalon) covers the same ground for newcomers. ## What the published record has actually measured Across twenty-five years of work, the Epitalon literature has accumulated three reproducible signals. First, in cultured human cells, AEDG induces expression of the telomerase catalytic subunit hTERT and elongates telomeres — first shown by Khavinson, Bondarev and Butyugov in fetal fibroblasts in 2003 [1] and independently replicated in normal human fibroblasts and epithelial cells by Al-dulaimi and colleagues in *Biogerontology* in 2025 [2]. Second, in rodent geroprotection models, monthly subcutaneous courses at microgram-per-mouse doses have reduced spontaneous tumor frequency in HER-2/neu mice [4], suppressed dimethylhydrazine-induced colon adenocarcinomas in rats [8], and slowed reproductive ageing in Swiss-derived SHR mice without increasing mean lifespan [6]. Third, in elderly human subjects with reduced pineal output, intramuscular courses of the parent extract Epithalamin restored night-time melatonin secretion toward younger-adult patterns [11][12]. The fine print matters: most of this work originates from a single program. ## Ala-Glu-Asp-Gly (AEDG): The Tetrapeptide Sequence AEDG is the single-letter shorthand for the amino-acid sequence of Epitalon: Alanine–Glutamate–Aspartate–Glycine. Researchers and chemists use 'AEDG peptide' and 'Epitalon' interchangeably in the literature, and the [AEDG peptide sequence](/#aedg) is the structural identifier referenced in most modern Western-indexed papers. The molecule is short and linear, without disulfide bridges or post-translational modifications — four amino acids joined by three peptide bonds, with a free amine at the N-terminus and a free carboxylate at the C-terminus. The 2020 *Molecules* paper by Khavinson and colleagues proposed a histone-binding mechanism for AEDG, modelling preferential interactions with histones H1/3 and H1/6 at their DNA-interactive sites [3]. The 2025 Araj review in the *International Journal of Molecular Sciences* consolidates the structural literature and explicitly notes that formal physicochemical characterisation of the intact tetrapeptide remains an open research gap [15]. ## Chemical identity The tetrapeptide is fully described by sequence H-Ala-Glu-Asp-Gly-OH, molecular formula `C14H22N4O9`, molar mass 390.35 g/mol, and CAS registry 307297-39-8 for the TFA salt commonly used in research [15]. The IUPAC name is (4S)-4-[[(2S)-2-aminopropanoyl]amino]-5-[[(2S)-3-carboxy-1-(carboxymethylamino)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid. As a short, unmodified linear peptide, oral bioavailability of the intact molecule is expected to be poor — and most published work uses parenteral routes (subcutaneous, intramuscular, parabulbar) or in vitro delivery [15]. ## What is Epitalon? Epitalon is the synthetic tetrapeptide Ala-Glu-Asp-Gly (AEDG), developed by Vladimir Khavinson's group in St. Petersburg from the amino-acid composition of the bovine pineal extract Epithalamin [1]. It is studied in the peer-reviewed literature as a putative telomerase activator, a modulator of pineal melatonin rhythm, and a candidate geroprotector in rodent models [2][6][11][15]. It is not an FDA-approved drug for any human indication. ## Research uses Epitalon is studied as a research tool for telomerase activation in human somatic cell lines [1][2], pineal melatonin regulation in aged subjects [11][12], antitumor effects in rodent models [4][7][8], and as a probe for cellular-aging biomarkers including hTERT expression, telomere length, and oxidative-stress indices [15]. It is not studied — in the peer-reviewed literature — as a cosmetic or appearance-modifying compound; reports of that kind circulate in consumer media but are not anchored to peer-reviewed clinical trial endpoints [15]. ## How to read this site The dossier is organised by what the studies measured. The [Epitalon mechanism of action](/research#mechanism) page walks through the telomerase-induction and histone-binding evidence. The [dosing in published studies](/dosage) page catalogues the routes and doses reported across rodent and human work, with no clinical recommendation attached. The [frequently asked questions](/faq) page collects the questions most often asked about the compound — including [reported side effects](/faq#side-effects), regulatory status, and the realistic limits of what the literature supports. The [Khavinson peptide program](/research#khavinson) section frames the historical context: this is a Russian peptide-bioregulator program with a long internal record and a thin external replication base, and reading the literature without that context produces misleading certainty in either direction. --- A textile-layered editorial digest of the Khavinson pineal tetrapeptide literature — Epitalon and Epithalon read as one molecule, two spellings, and twenty-five years of mostly-Russian record, with the Western trial gap named. --- # Epithalon (Epitalon): The Pineal Tetrapeptide in the Research Literature > Epithalon and Epitalon are spellings of the same AEDG tetrapeptide — the synthetic pineal peptide designed by Vladimir Khavinson's group. A literature digest of the telomerase, melatonin, and rodent-cohort evidence. Two spellings, one molecule — the AEDG tetrapeptide of the Khavinson St. Petersburg program, read against twenty-five years of peer-reviewed work. ## Epitalon vs Epithalon: same molecule, two spellings Epithalon and Epitalon are the same tetrapeptide — Ala-Glu-Asp-Gly (AEDG), molecular formula `C14H22N4O9`, molar mass 390.35 g/mol [15]. 'Epithalon' is the more common transliteration from the Russian literature and is the spelling preferred by most peptide databases and search-engine query volume. 'Epitalon' is the simplified English form, the spelling used by Wikipedia, and the form embedded in this domain. Both spellings appear in the PubMed record, sometimes within the same paper title — the seminal 2003 paper from Khavinson, Bondarev and Butyugov is indexed as 'Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells' [1], while the 2002 mammary-tumor paper from Anisimov and colleagues is indexed as 'Inhibitory effect of the peptide epitalon...' [4]. The same molecule, the same lab, two spellings of the same Russian noun. ## Spelling variants: Epitalon, Epithalon, Epithalone All three are spellings of the same AEDG tetrapeptide. 'Epithalon' and 'Epithalone' are transliterations from Cyrillic; 'Epitalon' is the simplified English form Wikipedia uses [15]. 'Epithalone' (with a terminal 'e') turns up in older Russian-program review articles. None of the spellings denote a different molecule, dose, or formulation — they denote the same defined-sequence synthetic tetrapeptide that the Khavinson program has worked with since the 1980s [14]. ## Why the spelling discrepancy persists Russian-to-English transliteration of biomedical terminology is unstandardised. The Russian noun for the molecule contains a Cyrillic 'th' analog that some translators render as 'th' and others elide to 't'. PubMed's controlled vocabulary does not collapse the variants, so a thorough literature search has to query both spellings — and at least one Khavinson-group paper in *Bulletin of Experimental Biology and Medicine* uses both spellings in the same article [1]. Modern Western papers (Al-dulaimi 2025, Araj 2025) standardise on 'Epitalon' in the abstract and title but acknowledge 'Epithalon' as the prior literature's preferred form [2][15]. ## Why this matters for reading the literature Anyone trying to read the Epitalon record seriously has to search both spellings. A PubMed query for 'Epitalon' returns roughly the modern Western-indexed papers and the Anisimov 2002 series; a query for 'Epithalon' returns the Khavinson 2003 seminal telomerase paper, the Korkushko 2004 elderly-melatonin cohort, and several of the Russian-language review articles indexed in English [1][11]. Missing either spelling produces a partial reading. This site uses 'Epitalon' as the canonical site spelling (matching the domain) and 'Epithalon' as the recurring co-mention, because both spellings appear in the publication record and conflating them obscures the literature's geography. ## What the 'Epithalon' spelling tends to mark In the peer-reviewed record, the 'Epithalon' spelling clusters with the Russian-program work — the Khavinson 2003 telomerase paper [1], the Korkushko 2004 elderly-cohort melatonin paper [11], the 2007 illumination-regime rat-lifespan paper [10], and the Khavinson 2002 retinitis pigmentosa series [13]. The 'Epitalon' spelling clusters with the Anisimov-led cancer-model series in *International Journal of Cancer* and *Cancer Letters* [4][8] and with the 2025 Western replications [2][15]. Functionally there is no molecular distinction — the spelling cue is a publication-venue cue, not a chemistry cue. ## How the spelling affects search and citation DataForSEO returns roughly 8,100 monthly queries for 'Epithalon' and a markedly smaller volume for 'Epitalon' — the spelling with an h carries the dominant consumer search intent. PubMed, in contrast, indexes both spellings with the variant preserved exactly as the author submitted. For literature work, query both spellings. For consumer-facing reading, the 'Epithalon' spelling will surface most non-academic results. Citation practice on this site preserves the spelling each author used in the original title — a small editorial fidelity that helps a reader trace papers back to their indexed forms. ## Reading both spellings forward The rest of this dossier uses 'Epitalon' for site-prose continuity and 'Epithalon' where the cited paper uses that spelling — which means both appear throughout the [research page](/research), the [dosage page](/dosage), and the [frequently asked questions](/faq). When the AEDG peptide is named in a paper title, this site preserves the title's spelling without normalisation. The molecule is one. The vocabulary, for historical and translational reasons, is two. --- A textile-layered editorial digest of the Khavinson pineal tetrapeptide literature — Epitalon and Epithalon read as one molecule, two spellings, and twenty-five years of mostly-Russian record, with the Western trial gap named. --- # What Is Epitalon? A Definitional Overview of the AEDG Tetrapeptide — Epitalon (Epithalon) > What is Epitalon? A definitional overview of the synthetic AEDG tetrapeptide — sequence, origin in the Khavinson St. Petersburg program, and the cellular and rodent-model evidence base. A tight, citation-anchored answer to the most-asked question about this Russian pineal-bioregulator compound — sequence, origin, mechanism, and the literature's honest limits. ## The one-paragraph definition Epitalon is a synthetic tetrapeptide with the amino-acid sequence Ala-Glu-Asp-Gly (AEDG), developed in the late 1980s and 1990s by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology [1][14]. The molecule was designed from the amino-acid composition of Epithalamin — a crude polypeptide extract of the bovine pineal gland that the Khavinson program had been studying as a putative geroprotector — and represents the defined-sequence synthetic fraction proposed to carry the parent extract's activity [11]. It is studied as a putative telomerase activator, a pineal-axis modulator, and a candidate geroprotector in rodent models [2][6][15]. ## Sequence and chemistry The molecule is a linear tetrapeptide of four amino acids — alanine, glutamate, aspartate, glycine — joined by three peptide bonds. Molecular formula `C14H22N4O9`, molar mass 390.35 g/mol, CAS registry 307297-39-8 for the TFA salt commonly used in research [15]. There are no disulfide bridges, no glycosylation, no other post-translational modifications. The compound's small size and short linear structure make it cheap to synthesise and easy to characterise structurally — but also imply rapid proteolytic clearance in plasma, which has shaped how it is administered in the published studies (parenteral routes dominate; oral bioavailability of the intact peptide is expected to be poor) [15]. ## Origin: from Epithalamin to AEDG The Khavinson program began with Epithalamin — a polypeptide extract of bovine pineal gland — in the 1970s and 1980s, reporting effects on melatonin secretion, immune function, and reproductive ageing in rodents and elderly humans [11][12][14]. The synthetic AEDG tetrapeptide was designed to reproduce the parent extract's activity in a defined-sequence form that could be cleanly characterised, dosed, and (in principle) regulated. Where Epithalamin is a complex biological mixture, Epitalon is a single defined molecule — and a substantial portion of the 'Epitalon' clinical claims in the consumer literature are actually claims about Epithalamin that have been extrapolated to its synthetic fraction [11]. ## What the cellular evidence shows In cultured human cells, AEDG induces expression of the telomerase catalytic subunit hTERT and elongates telomeres. The seminal demonstration came from Khavinson, Bondarev and Butyugov in *Bulletin of Experimental Biology and Medicine* in 2003 — fetal fibroblasts, telomerase-negative at baseline, became telomerase-active after exposure to the peptide [1]. The finding was independently replicated by Al-dulaimi and colleagues in *Biogerontology* in 2025 in normal human fibroblasts (IBR.3) and human mammary epithelial cells (HMEC), with telomere elongation directly measured; in breast cancer lines the same exposure produced little change in telomerase but roughly a ten-fold rise in ALT-pathway activity in 21NT cells [2]. The 2020 Khavinson *Molecules* paper proposed a histone-binding mechanism, with molecular modelling supporting preferential binding to histones H1/3 and H1/6 at their DNA-interactive sites [3]. ## What the animal evidence shows In rodent geroprotection models, monthly subcutaneous courses at microgram-per-mouse doses have produced reproducible effects on tumor frequency and reproductive ageing. In female HER-2/neu transgenic mice, monthly 5-day courses of 1 microgram/mouse reduced cumulative tumor number and maximum mammary-tumor size versus saline controls [4]; tumor size dropped by 33% in a parallel cohort with a 3.7-fold reduction in HER-2/neu mRNA [5]. In Swiss-derived SHR mice, the same monthly protocol slowed reproductive ageing and reduced chromosome-aberration frequency in bone marrow by 17.1%, without changing mean lifespan [6]. In C3H/He mice, six-and-a-half months of 0.1 microgram/mouse five days per week reduced malignant-tumor incidence and prevented metastases without observable toxicity [7]. ## What the human evidence shows — and where it stops The human evidence is real but limited. Korkushko and colleagues reported in 2004 that intramuscular Epithalamin courses normalised night-time melatonin secretion in elderly subjects with pineal hypofunction [11], and the 2007 multi-cohort report extended the finding across aged rhesus monkeys and elderly humans [12]. A small parabulbar-injection series in retinitis pigmentosa patients reported improved bioelectric retinal activity in 90% of cases [13]. No large, modern, registered Western randomised controlled trials of the synthetic AEDG tetrapeptide appear on ClinicalTrials.gov as of 2026 [15]. The honest reading: the cellular and rodent evidence is reproducible; the human evidence is real but small, mostly Russian-language, and not yet at the level of modern regulatory drug development. ## The literature's geography matters Most of the positive in vivo and cohort data originate from a single research program — the Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology. The 2025 Araj review in *International Journal of Molecular Sciences* makes the point explicitly: twenty-five years of work, a consistent mechanistic and rodent record, but pharmacokinetic characterisation, modern toxicology packages, and large Western human trials remain absent [15]. A reader looking for FDA-grade evidence will not find it. A reader looking for a reproducible cellular signal and a consistent rodent geroprotection signature, with one independent 2025 cell-line replication, will find that. --- A textile-layered editorial digest of the Khavinson pineal tetrapeptide literature — Epitalon and Epithalon read as one molecule, two spellings, and twenty-five years of mostly-Russian record, with the Western trial gap named. --- # Epitalon Research: Telomerase, Pineal Melatonin, and the Khavinson Peptide Program > Epitalon research summarised: hTERT induction in human cell lines, melatonin restoration in elderly cohorts, rodent cancer-model results, and the historical context of the Khavinson St. Petersburg peptide program. An organised reading of the peer-reviewed evidence — cellular mechanism first, animal models second, the small human cohort record third, and the historical Khavinson program as context. ## Epitalon Mechanism of Action The Epitalon mechanism of action centres on three proposed pathways, layered from most directly evidenced to most inferred. First and most reproducibly: induction of hTERT expression and telomerase activity in human somatic cells, with telomere elongation as the downstream measurement [1][2]. Second: direct binding to DNA promoter regions and to histone proteins — the 2020 Khavinson *Molecules* paper used molecular modelling to propose preferential AEDG binding to histones H1/3 and H1/6 at their DNA-interactive sites, with downstream upregulation of neurogenic differentiation markers (Nestin, GAP43, β-tubulin III, Doublecortin) by 1.6 to 1.8-fold in human gingival mesenchymal stem cells [3]. Third: restoration of nocturnal melatonin secretion in subjects with pineal hypofunction, demonstrated for the parent extract Epithalamin in elderly humans [11] and the AEDG-related preparation in aged rhesus monkeys [12]. ## Epitalon and Telomerase Activation The single most-cited mechanism for Epitalon is telomerase activation. In 2003, Khavinson, Bondarev and Butyugov reported in *Bulletin of Experimental Biology and Medicine* that adding the peptide to telomerase-negative human fetal fibroblast cultures induced expression of the telomerase catalytic subunit, restored enzymatic telomerase activity, and elongated telomeres in previously telomerase-silent cells [1]. The finding sat in the literature largely unreplicated outside the Khavinson program for two decades. In 2025, Al-dulaimi and colleagues published an independent replication in *Biogerontology*: in normal human fibroblasts (IBR.3) and mammary epithelial cells (HMEC), AEDG upregulated hTERT mRNA and telomerase activity with telomere length increase; in breast cancer cell lines (21NT and BT474) the same exposure produced little change in telomerase enzymatic activity but a roughly ten-fold rise in ALT (Alternative Lengthening of Telomeres) activity in the 21NT line [2]. The differential — telomerase upregulation in normal cells, ALT activation in some cancer lines — is one of the open questions the modern literature has raised. ## Proposed telomerase-activation mechanism The proposed model: AEDG binds to specific gene promoter regions and increases hTERT transcription, leading to elongation of telomeric repeats in cultured human cells [1][3]. The 2020 epigenetic-mechanism paper from the Khavinson group provided the histone-binding refinement — molecular docking predicted AEDG binds histones H1/3 and H1/6 at their DNA-contact surfaces, suggesting a chromatin-level rather than purely transcription-factor-level intervention [3]. The mechanism remains under active investigation; the 2025 Araj review explicitly identifies the precise binding-and-transcription cascade as an outstanding question even after twenty-five years of work [15]. ## Epithalamin vs Epitalon: From Pineal Extract to Synthetic Tetrapeptide Epithalamin and Epitalon are not interchangeable. Epithalamin is a crude polypeptide extract of bovine pineal gland — a complex mixture of peptides and amino acids — that the Khavinson program studied from the 1970s onward, with reported effects on melatonin rhythm, immune function, and lifespan in animal models [11][14]. Epitalon is the synthetic defined-sequence tetrapeptide AEDG, designed from the amino-acid profile of Epithalamin to reproduce a portion of its activity in a chemically clean form [14]. Most of the clinical-cohort data attributed in consumer media to 'Epitalon' is in fact data on Epithalamin — the 2004 Korkushko elderly-melatonin paper, for example, dosed intramuscular Epithalamin and reported melatonin normalisation in subjects with pineal hypofunction [11]. The distinction is not a quibble: a crude extract has a different regulatory, pharmacokinetic, and reproducibility profile than a defined synthetic peptide. ## The Khavinson Peptide Program and the Origin of Epitalon Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology developed Epitalon in the late 1980s and 1990s as part of a broader research program on short peptide bioregulators [1][14]. The program's working hypothesis: short peptides derived from tissue extracts act as tissue-specific gene-expression regulators, restoring function in age-impaired tissues. Epitalon was the pineal-derived member of a family that also includes Thymalin (thymus-derived), Vilon (immune), and Cortexin (cortex-derived). The 2002 *Neuro Endocrinology Letters* supplement-length monograph 'Peptides and Ageing' by Khavinson is the program's narrative summary: twenty-five years of work across rodent lifespan, primate melatonin, and small elderly cohorts, reported predominantly in Russian-language and Bulletin-of-Experimental-Biology-and-Medicine venues [14]. Independent Western replication of the lifespan and cohort-mortality findings remains limited. ## Pineal Gland Origin and Melatonin Effects Epitalon's pineal origin runs through both its design history and its proposed mechanism. The parent extract Epithalamin was prepared from bovine pineal gland, and the AEDG sequence was designed from that extract's amino-acid composition [14]. The pineal-axis pharmacology is the most heavily studied human-cohort endpoint: Korkushko and colleagues in 2004 reported that intramuscular Epithalamin courses normalised night-time melatonin secretion in elderly subjects, with subjects having reduced baseline pineal activity showing the largest increases and subjects with preserved baseline showing a downward trend [11]. The 2007 multi-cohort extension reported similar melatonin-normalisation in aged rhesus monkeys treated with pineal-peptide preparations [12]. Whether the synthetic AEDG tetrapeptide alone (as opposed to the parent extract) produces the same melatonin signal in a modern controlled human trial remains untested in the published Western record. ## Reported effects in the published literature Studied effects in the peer-reviewed record cluster into four families. Cellular: telomerase induction, telomere elongation, ALT-pathway differential in cancer lines [1][2]. Genomic-regulatory: histone binding and upregulation of neurogenic differentiation markers in mesenchymal stem cells [3]. Rodent geroprotection: reduced spontaneous tumor frequency in HER-2/neu mice [4][5], reduced DMH-induced colon carcinogenesis in LIO rats [8], reduced malignant-tumor incidence and metastasis prevention in C3H/He mice [7], slowed reproductive ageing in SHR mice with cytogenetic-damage reduction [6], modified survival under altered illumination regimes [10], extended maximum lifespan in the longest-living 10% of SAMP-1 mice [9]. Human cohort: melatonin rhythm normalisation in elderly subjects with pineal hypofunction [11][12], improved bioelectric retinal activity in 90% of a retinitis pigmentosa series [13]. ## Animal-model evidence Rodent geroprotection is the densest portion of the Epitalon record. In female HER-2/neu transgenic mice, monthly 5-day courses of 1 microgram/mouse subcutaneous reduced cumulative tumor number and maximum mammary-tumor size versus saline (p < 0.05) and reduced HER-2/neu oncogene mRNA by 3.7-fold [4][5]. In Swiss-derived SHR mice on the same monthly protocol from age 3 months, the peptide slowed age-related estrous-function loss and reduced chromosome-aberration frequency in bone-marrow cells by 17.1%; mean lifespan was unchanged, with the cumulative ~30-40 microgram/kg monthly exposure [6]. In C3H/He mice, 0.1 microgram/mouse five days per week for 6.5 months reduced malignant-tumor incidence and prevented metastases without observable toxicity [7]. In male LIO rats, weekly subcutaneous Epitalon alongside DMH challenge (21 mg/kg) suppressed colon-adenocarcinoma multiplicity and size [8]. In SAMP-1 senescence-accelerated mice, both melatonin and Epitalon preserved estrous cycling; Epitalon extended maximum lifespan in the longest-living 10% of animals without shifting overall tumor incidence [9]. In LIO rats under varying illumination regimes, monthly Ala-Glu-Asp-Gly (0.1 microgram/rat) partly compensated the lifespan-shortening effect of constant light [10]. ## Human studies Human studies of Epitalon and its parent extract Epithalamin exist but are limited in number, geographic distribution, and methodological scale. The Korkushko 2004 paper in *Bulletin of Experimental Biology and Medicine* reported that intramuscular Epithalamin courses normalised nocturnal melatonin secretion in elderly subjects with reduced pineal function [11]. The 2007 *Advances in Gerontology* multi-cohort paper extended the melatonin-normalisation finding across aged rhesus monkeys and elderly humans [12]. The 2002 retinitis pigmentosa series in *Neuro Endocrinology Letters* reported that parabulbar Epitalon (5 micrograms per eye for 10 consecutive days) improved bioelectric retinal activity and produced positive clinical response in 90% of treated patients [13]. As of 2026, ClinicalTrials.gov lists no large, modern, registered Western randomised controlled trials of the synthetic AEDG tetrapeptide [15] — and the 2025 Araj review in *International Journal of Molecular Sciences* identifies the absence of modern human trials as a primary outstanding gap [15]. ## What does Epitalon do at the cellular level? At the cellular level, Epitalon induces telomerase activity and telomere elongation in human somatic cell lines — replicated across the seminal 2003 Khavinson fetal-fibroblast work and the 2025 Al-dulaimi normal-fibroblast and epithelial-cell replication [1][2]. In stem cells, the peptide upregulates neurogenic differentiation markers via a proposed epigenetic mechanism of histone H1/3 and H1/6 binding [3]. In some cancer cell lines, the peptide selectively activates the ALT (Alternative Lengthening of Telomeres) pathway rather than telomerase — a differential first reported in the 2025 Biogerontology paper [2]. ## Recent findings Two 2025 papers reset the modern reading of the literature. The Al-dulaimi *Biogerontology* paper provided the first major Western-indexed independent replication of telomere elongation in human cell lines via hTERT upregulation, with the additional ALT-pathway finding in breast cancer lines [2]. The Araj *International Journal of Molecular Sciences* review (Volume 26, Article 2691) consolidated twenty-five years of Epitalon evidence — geroprotective, antioxidant, neuroprotective, antimutagenic — and identified the unresolved gaps: validated pharmacokinetic data, modern toxicology packages, large registered human trials [15]. The 2020 *Molecules* paper proposing the histone-binding epigenetic mechanism remains the structural-mechanism reference [3]. --- A textile-layered editorial digest of the Khavinson pineal tetrapeptide literature — Epitalon and Epithalon read as one molecule, two spellings, and twenty-five years of mostly-Russian record, with the Western trial gap named. --- # Epitalon Dosing in Published Studies: Routes, Ranges, and Pharmacokinetic Notes > Epitalon dosing in the published research literature: rodent microgram-per-mouse subcutaneous protocols, Russian human-cohort intramuscular courses, parabulbar ophthalmic series, and the unresolved pharmacokinetic record. A reading of routes, doses, and durations across rodent cancer models, Russian elderly cohorts, and small ophthalmic series — described as published research dosing, not as clinical recommendation. ## The dosing summary in one paragraph Epitalon dosing in the published peer-reviewed literature falls into three buckets. Rodent geroprotection studies dominate: monthly 5-day subcutaneous courses at 0.1 to 1.0 microgram per mouse (roughly 4 to 40 microgram/kg in a 25 g mouse), repeated across years of life [4][6][7][9]. Russian human-cohort reports describe short intramuscular courses of the parent pineal extract Epithalamin in elderly subjects — typically on the order of 10 mg per injection, 5 injections per course, repeated periodically — with measured endpoints around melatonin secretion [11]. A small ophthalmic series in retinitis pigmentosa patients used parabulbar Epitalon at 5 micrograms per eye for 10 consecutive days [13]. All described below as published study dosing, not as personal clinical recommendation. ## Doses used in published studies Rodent studies overwhelmingly use microgram-per-mouse subcutaneous dosing on monthly cycles. Anisimov 2002 in *International Journal of Cancer*: 1 microgram per mouse subcutaneous, 5 consecutive days every month, in female HER-2/neu transgenic mice [4]. Anisimov 2003 in *Biogerontology*: 1 microgram per mouse subcutaneous, 5 consecutive days every month, from age 3 months, in female SHR mice (cumulative monthly exposure ~30-40 microgram/kg) [6]. Kossoy 2006 in *In Vivo*: 0.1 microgram per mouse subcutaneous, 5 days per week for 6.5 months, in 1-year-old female C3H/He mice [7]. Vinogradova 2007 in *Bulletin of Experimental Biology and Medicine*: 0.1 microgram per rat subcutaneous, 5 days per month, in female outbred LIO rats [10]. Russian human-cohort intramuscular courses of Epithalamin typically reported around 10 mg per injection with 5 injections per course [11]. Parabulbar ophthalmic series: 5 micrograms per eye, 10 consecutive days [13]. ## Routes of administration in published work Routes studied in the peer-reviewed literature include subcutaneous (the dominant rodent route) [4][6][7][8], intramuscular (the dominant human-cohort route for Epithalamin courses) [11], intraperitoneal (some rat protocols), parabulbar/peri-ocular (the retinitis pigmentosa series at 5 microgram per eye for 10 days) [13], and intranasal (reported in some Russian work). In vitro cell-culture exposure is used in all the mechanism studies [1][2][3]. Oral bioavailability of the intact tetrapeptide is expected to be poor and has not been formally validated in the peer-reviewed Western record [15]. ## Epitalon half-life and pharmacokinetics Validated plasma half-life data for the intact AEDG tetrapeptide is sparse in the PubMed-indexed literature. As a short, unmodified linear peptide, rapid serum proteolysis is expected — clearance on the order of minutes to low single-digit hours rather than days [15]. The 2025 Araj review in *International Journal of Molecular Sciences* identifies validated pharmacokinetic characterisation as one of the primary outstanding research gaps for the compound: 'formal physicochemical characterisation and modern human safety/toxicology data remain limited' [15]. No human PK study with formal AUC, Cmax, or half-life values for the synthetic tetrapeptide is published in the indexed Western literature as of 2026. The most-honest reading is that the molecule's PK is plausible — short linear peptide, parenteral routes, rapid proteolysis — but unvalidated. ## How is Epitalon administered in studies? In published studies, subcutaneous and intramuscular injection are the most commonly reported routes [4][6][7][8][11]. Intranasal delivery has been examined in some Russian-program work. Parabulbar (peri-ocular) injection was used in the retinitis pigmentosa series [13]. In vitro cell-culture exposure is the standard route in mechanism work [1][2][3]. Oral bioavailability of the intact tetrapeptide is expected to be poor and has not been formally validated; no oral-route human dosing study appears in the PubMed-indexed Western record [15]. ## Stability and formulation notes Epitalon is a short linear tetrapeptide without disulfide bridges or post-translational modifications. Most published research work uses parenteral delivery (subcutaneous, intramuscular, intraperitoneal, parabulbar) precisely because oral bioavailability of intact short peptides is generally low and is not formally validated for this compound [15]. The TFA salt (CAS 307297-39-8) is the form commonly used in research synthesis [15]. Storage and reconstitution practices in the published rodent work typically use lyophilised peptide reconstituted in physiological saline before subcutaneous injection. ## Duration and cycle structures in the rodent work Rodent geroprotection studies use long-duration cyclic dosing. The canonical Khavinson-program protocol — monthly 5-day courses, repeated across years of an animal's life — appears in the Anisimov 2002 HER-2/neu mammary-tumor study [4], the Anisimov 2003 SHR mouse reproductive-ageing study [6], the Vinogradova 2007 illumination-regime study [10]. The Kossoy 2006 study used a more frequent schedule — 5 days per week for 6.5 months — and reported reduced malignant-tumor incidence and metastasis prevention without observable toxicity [7]. Across these protocols, cumulative annual exposure ranges from roughly 60 micrograms per mouse per year (monthly 5-day at 1 microgram/mouse) to roughly 130 micrograms per mouse over the 6.5-month Kossoy protocol [4][7]. Mean lifespan was not increased in the SHR mouse cohort even at the multi-year exposure [6]. --- A textile-layered editorial digest of the Khavinson pineal tetrapeptide literature — Epitalon and Epithalon read as one molecule, two spellings, and twenty-five years of mostly-Russian record, with the Western trial gap named. --- # Epitalon FAQ: Telomerase, Spelling, Dosing, Safety, and Regulatory Status > Epitalon frequently asked questions: what the AEDG tetrapeptide is, how it differs from Epithalamin, what dosing has been used in studies, what side effects have been reported, and where the literature's limits actually fall. The questions actually asked about Epitalon — definitional, mechanistic, dosing, safety, regulatory — answered in 40-80 words each, with every quantitative claim cited. ## Definitional ### What is Epitalon? Epitalon is a synthetic tetrapeptide with sequence Ala-Glu-Asp-Gly (AEDG), developed by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology from the amino-acid composition of the bovine pineal extract Epithalamin [1][14]. It is studied as a putative telomerase activator and as a candidate geroprotector in rodent models [2][15]. It is not an FDA-approved drug for any human indication. ### What is the difference between Epitalon and Epithalon? They are the same tetrapeptide (Ala-Glu-Asp-Gly). 'Epithalon' is the more common transliteration from the Russian literature and the spelling preferred by most peptide databases. 'Epitalon' is the simplified spelling used by Wikipedia and embedded in this domain [15]. Both spellings appear in the PubMed record, sometimes within the same paper [1][4]. ### What is the difference between Epitalon and Epithalamin? Epithalamin is a crude polypeptide extract of bovine pineal gland — a complex biological mixture. Epitalon is the synthetic defined-sequence tetrapeptide AEDG, designed to reproduce a portion of Epithalamin's activity in a chemically clean form [14]. Most published human-cohort melatonin data is on Epithalamin, not on the synthetic tetrapeptide [11]. ### What is the difference between Epitalon and Epithalone? All three — Epitalon, Epithalon, Epithalone — are spellings of the same AEDG tetrapeptide. 'Epithalon' and 'Epithalone' are transliterations from Cyrillic; 'Epitalon' is the simplified English form Wikipedia uses [15]. The variant terminal 'e' in 'Epithalone' appears in some older Russian-program review articles; the molecule is identical. ### What is the AEDG peptide? AEDG is the single-letter shorthand for the amino-acid sequence of Epitalon: Alanine-Glutamate-Aspartate-Glycine. Researchers and chemists use 'AEDG peptide' and 'Epitalon' interchangeably in the peer-reviewed literature [1][3][15]. The molecule is a linear tetrapeptide with molecular formula `C14H22N4O9` and molar mass 390.35 g/mol. ### What is Epitalon's chemical structure? Tetrapeptide with sequence H-Ala-Glu-Asp-Gly-OH. Molecular formula `C14H22N4O9`, molar mass 390.35 g/mol, CAS 307297-39-8 for the TFA salt commonly used in research [15]. It is a short linear peptide without disulfide bridges or other post-translational modifications. ### What is the chemical formula of Epitalon? Molecular formula `C14H22N4O9`. Molar mass 390.35 g/mol. CAS registry 307297-39-8 for the TFA salt commonly used in research synthesis [15]. The molecule is a four-amino-acid linear peptide (Ala-Glu-Asp-Gly) with no post-translational modifications. ## Mechanism ### What does Epithalon peptide do? In vitro work shows induction of telomerase activity and telomere elongation in human somatic cell lines — first reported by Khavinson, Bondarev and Butyugov in 2003 and independently replicated by Al-dulaimi and colleagues in *Biogerontology* in 2025 [1][2]. Animal work suggests effects on melatonin rhythms, antioxidant pathways, and spontaneous tumor incidence in rodent geroprotection models [4][6][7]. ### How does Epitalon activate telomerase? Proposed model: AEDG binds to specific gene promoter regions and to histone proteins (notably H1/3 and H1/6 at their DNA-interactive sites), increasing hTERT expression and leading to elongation of telomeric repeats in cultured human cells [1][3]. The mechanism remains under active investigation; the 2025 Araj review identifies the precise binding-and-transcription cascade as an outstanding question [15]. ### What is the mechanism of action of Epitalon? Proposed mechanisms include direct binding to specific DNA promoter regions, induction of hTERT expression and telomerase activity, restoration of pineal melatonin circadian rhythm in pineal-hypofunctional subjects, and modulation of antioxidant defence markers [1][3][11][15]. The 2020 *Molecules* paper proposed a histone-binding epigenetic refinement based on molecular modelling [3]. ## Evidence ### What are the benefits of Epithalon in the research literature? Studied effects in the peer-reviewed record include telomerase induction in human cell lines [1][2], reduced spontaneous tumor frequency in HER-2/neu mice [4][5], suppressed colon carcinogenesis in rats [8], slowed reproductive ageing in SHR mice [6], and melatonin-rhythm normalisation in elderly subjects with pineal hypofunction [11]. Human data is limited to small, mostly Russian-language cohort studies. ### Has Epitalon been studied in humans? Yes — primarily in Russian-language cohort studies coordinated by the Khavinson group, with reported endpoints around melatonin circadian rhythm and elderly geriatric function [11][12]. A small parabulbar-injection series in retinitis pigmentosa patients also exists [13]. Large, modern, registered Western randomised controlled trials are absent from ClinicalTrials.gov as of 2026 [15]. ### Has Epitalon been studied in animal models? Yes — multiple rodent studies report effects on spontaneous tumor frequency [4][5][7], DMH-induced colon carcinogenesis [8], reproductive ageing and chromosome-aberration frequency [6], maximum lifespan in senescence-accelerated mice [9], and survival under altered illumination regimes [10]. Most published in *Bulletin of Experimental Biology and Medicine* and English-language Khavinson-program reviews [14]. ### What does the most recent research on Epitalon show? Two 2025 papers anchor the modern reading. Al-dulaimi and colleagues in *Biogerontology* independently replicated telomere elongation in normal human cell lines via hTERT upregulation, with selective ALT-pathway activation in breast cancer lines [2]. The Araj review in *International Journal of Molecular Sciences* consolidated twenty-five years of evidence and identified pharmacokinetics, toxicology, and modern human trials as outstanding gaps [15]. ### What is Epitalon used for in research? In the peer-reviewed literature, Epitalon is used as a research probe for telomerase activation in human cell lines [1][2], pineal melatonin regulation in aged subjects [11][12], antitumor effects in rodent geroprotection models [4][7][8], and biomarkers of cellular ageing including hTERT expression, telomere length, and oxidative-stress indices [15]. ### Who developed Epitalon? Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology synthesised Epitalon in the late 1980s and 1990s, designed from the amino-acid composition of the bovine pineal extract Epithalamin [1][14]. Khavinson's 2002 *Neuro Endocrinology Letters* supplement-length monograph 'Peptides and Ageing' remains the program's narrative summary [14]. ## Dosing and pharmacokinetics ### What dosing regimens have been used in Epitalon studies? Rodent protocols commonly report 0.1 to 1.0 microgram per mouse subcutaneous, 5 consecutive days per month, across years of life [4][6][7]. Russian human-cohort reports describe intramuscular courses of the parent extract Epithalamin — typically around 10 mg per injection, 5 injections per course, repeated periodically [11]. All described as published study dosing, not as clinical recommendation. ### What is Epitalon's half-life? Validated plasma half-life data for the intact tetrapeptide is sparse in PubMed-indexed literature. As a short, unmodified linear peptide, rapid serum proteolysis is expected — clearance on the order of minutes to low single-digit hours [15]. The 2025 Araj review identifies pharmacokinetic characterisation as an outstanding research gap; no formal validated PK data in humans is published [15]. ### How long does Epithalon take to work? Published studies describe outcome measures evaluated over weeks to months following a short injection course; in vitro telomere-elongation work shows effects across multiple cell-division cycles [1][2]. There is no validated 'onset' figure for clinical effect in the modern indexed Western literature, and the 2025 Araj review explicitly flags the absence of formal PK/PD characterisation [15]. ### Time course of effects in studies In the rodent geroprotection record, outcome measures (tumor frequency, reproductive cycling, cytogenetic damage) are typically evaluated over months of monthly 5-day dosing across years of animal life [4][6][7]. In the elderly-cohort melatonin work, effects on nocturnal melatonin secretion are reported following short intramuscular Epithalamin courses on the order of 5 injections per course [11]. ### Cosmetic / appearance claims Does Epitalon make you look younger? Cosmetic claims about appearance are not the primary endpoint of the peer-reviewed Epitalon literature, which focuses on cellular and molecular markers (telomerase activity, telomere length, melatonin secretion, oxidative-stress indices) [1][2][11][15]. Anecdotal appearance reports in consumer media are not validated by clinical trial endpoints in the published record. ### Does Epitalon actually work? What does the evidence actually show? In vitro: replicable telomerase induction in human cell lines, including a 2025 Western-indexed independent replication [1][2]. In rodents: reduced spontaneous tumor frequency, lifespan effects in some cohorts but not others [4][6][9]. In humans: limited, mostly Russian-language data — real but not at the level of registered Western clinical trials [11][12][15]. ## Reported side effects in Epitalon studies ### What side effects have been reported in Epithalon studies? Russian cohort reports describe a generally favourable tolerability profile with no consistent severe adverse events documented across the published Epithalamin/Epitalon record [11][13]. Site-of-injection reactions are the most commonly mentioned issue. The 2025 Araj review explicitly notes that large, modern safety and toxicology data of the regulatory type are absent from the published literature [15]. ### What side effects have been reported with Epitalon? The peer-reviewed record reports a generally favourable tolerability profile in the Russian-program human cohorts and a clean rodent toxicity record in the long-duration studies tested (Kossoy 2006 reported no observable toxicity at 0.1 microgram/mouse five days/week for 6.5 months) [7][11]. Formal regulatory-grade toxicology, genotoxicity, and carcinogenicity packages are not in the public peer-reviewed literature [15]. ## Regulatory status of Epitalon ### Is Epitalon legal as a research chemical? Epitalon is not an FDA-approved drug in the United States for any human indication and is not approved by the EMA or other major Western regulators [15]. Outside Russia it is generally handled as a research chemical. In Russia, related pineal preparations have a history of use in geriatric medicine within the Khavinson program's institutional context [14]. Athletes should consult current WADA documentation directly. --- A textile-layered editorial digest of the Khavinson pineal tetrapeptide literature — Epitalon and Epithalon read as one molecule, two spellings, and twenty-five years of mostly-Russian record, with the Western trial gap named. --- # Epitalon References: Khavinson, Anisimov, Korkushko, Al-dulaimi, Araj — The Cited Literature > Epitalon references: the full cited literature for this dossier — Khavinson 2003 telomerase, Anisimov 2002 HER-2/neu cancer model, Korkushko 2004 elderly melatonin, Al-dulaimi 2025 replication, Araj 2025 review. Every paper cited across this site, with author lines, journal venue, year, DOI, and PubMed URL — restricted to PubMed-indexed English-language sources for traceability. ## How to read this list Each reference below corresponds to an inline [N] marker on a page of this site. Citations are restricted to PubMed-indexed English-language papers — even where the Khavinson program has published prolifically in Russian-language venues, this dossier cites only the indexed Western or English-language Bulletin-of-Experimental-Biology-and-Medicine translations. That editorial choice means some of the Russian-language cohort data summarised here is anchored to Khavinson's 2002 review monograph [14] and the 2025 Araj consolidation review [15] rather than to primary Russian-language sources directly. The trade-off is traceability. ## Numbered reference list All numbered references are listed in the page-level `references_index` block below — see the rendered references page for the full author, journal, year, DOI, and PubMed URL detail. ## References [1] Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-592. https://pubmed.ncbi.nlm.nih.gov/12937682/ [2] Al-dulaimi S, Thomas R, Matta S, Roberts T. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025. https://pubmed.ncbi.nlm.nih.gov/40908429/ [3] Khavinson V, Diomede F, Mironova E, Linkova N, Trofimova S, Trubiani O, Caputi S, Sinjari B. AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism. Molecules. 2020;25(3):609. https://pubmed.ncbi.nlm.nih.gov/32019204/ [4] Anisimov VN, Khavinson VKh, Provinciali M, Alimova IN, Baturin DA, Popovich IG, Zabezhinski MA, Imyanitov EN, Mancini R, Franceschi C. Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Int J Cancer. 2002;101(1):7-10. https://pubmed.ncbi.nlm.nih.gov/12209581/ [5] Anisimov VN, Khavinson VKh, Alimova IN, Provinciali M, Mancini R, Franceschi C. Epithalon inhibits tumor growth and expression of HER-2/neu oncogene in breast tumors in transgenic mice characterized by accelerated aging. Bull Exp Biol Med. 2002;133(2):167-170. https://pubmed.ncbi.nlm.nih.gov/12428286/ [6] Anisimov VN, Khavinson VKh, Popovich IG, Zabezhinski MA, Alimova IN, Rosenfeld SV, Zavarzina NYu, Semenchenko AV, Yashin AI. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology. 2003;4(4):193-202. https://link.springer.com/article/10.1023/A:1025114230714 [7] Kossoy G, Anisimov VN, Ben-Hur H, Kossoy N, Zusman I. Effect of the synthetic pineal peptide epitalon on spontaneous carcinogenesis in female C3H/He mice. In Vivo. 2006;20(2):253-257. https://iv.iiarjournals.org/content/20/2/253 [8] Anisimov VN, Khavinson VKh, Popovich IG, Zabezhinski MA. Inhibitory effect of peptide Epitalon on colon carcinogenesis induced by 1,2-dimethylhydrazine in rats. Cancer Lett. 2002;183(1):1-8. https://pubmed.ncbi.nlm.nih.gov/12049808/ [9] Anisimov VN, Popovich IG, Zabezhinski MA, Rosenfeld SV, Khavinson VKh, Semenchenko AV, Yashin AI. Effect of epitalon and melatonin on life span and spontaneous carcinogenesis in senescence accelerated mice (SAM). Vopr Onkol. 2005;51(1):93-98. https://pubmed.ncbi.nlm.nih.gov/15909815/ [10] Vinogradova IA, Bukalev AV, Zabezhinski MA, Semenchenko AV, Khavinson VKh, Anisimov VN. Effect of Ala-Glu-Asp-Gly peptide on life span and development of spontaneous tumors in female rats exposed to different illumination regimes. Bull Exp Biol Med. 2007;144(6):825-830. https://pubmed.ncbi.nlm.nih.gov/18856211/ [11] Korkushko OV, Khavinson VKh, Shatilo VB, Magdich LV. Effect of peptide preparation epithalamin on circadian rhythm of epiphyseal melatonin-producing function in elderly people. Bull Exp Biol Med. 2004;137(4):389-391. https://pubmed.ncbi.nlm.nih.gov/15452611/ [12] Korkushko OV, Lapin BA, Goncharova ND, Khavinson VKh, Shatilo VB, Vengerin AA, Antoniuk-Shcheglova IA, Magdich LV. Normalizing effect of the pineal gland peptides on the daily melatonin rhythm in old monkeys and elderly people. Adv Gerontol. 2007;20(1):74-85. https://pubmed.ncbi.nlm.nih.gov/17969590/ [13] Khavinson V, Razumovsky M, Trofimova S, Grigorian R, Razumovskaya A. Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa. Neuro Endocrinol Lett. 2002;23(4):365-368. https://pubmed.ncbi.nlm.nih.gov/12195242/ [14] Khavinson VKh. Peptides and Ageing. Neuro Endocrinol Lett. 2002;23 Suppl 3:11-144. https://pubmed.ncbi.nlm.nih.gov/12374906/ [15] Araj SK, Brzezik J, Madra-Gackowska K, Szeleszczuk L. Overview of Epitalon - Highly Bioactive Pineal Tetrapeptide with Promising Properties. Int J Mol Sci. 2025;26(6):2691. https://pubmed.ncbi.nlm.nih.gov/40141333/ --- A textile-layered editorial digest of the Khavinson pineal tetrapeptide literature — Epitalon and Epithalon read as one molecule, two spellings, and twenty-five years of mostly-Russian record, with the Western trial gap named. --- # About rx Epitalon: An Independent Editorial Digest of the AEDG Pineal Tetrapeptide Literature > About this site: rx Epitalon is an independent editorial digest of the peer-reviewed Epitalon and Epithalamin literature — a textile-layered reading of the Khavinson St. Petersburg program record. Not a clinic, not a vendor. A publication, not a practice — a hand-bound digest of what the Khavinson program and its Western replicators have actually measured. ## What this site is rx Epitalon is an independent editorial project that publishes summaries of the peer-reviewed research literature on Epitalon — the synthetic AEDG tetrapeptide designed by Vladimir Khavinson's St. Petersburg group [1][14]. The work is editorial commentary on publicly available science. The site is not a clinic. It does not employ clinicians and it does not provide medical advice. It does not manufacture, sell, or distribute any product. It is not affiliated with any peptide vendor or any pharmaceutical company. ## What the 'rx' in the name means — and does not mean The 'rx' prefix in the domain name is editorial framing — a position the publisher occupies relative to the literature, signalling the careful, citation-anchored register of the reading. It is not a claim about the site's services. This site does not write prescriptions. It does not consult with patients. It does not represent any prescribing clinician. The 'rx' is a typographic mark of editorial seriousness — the dossier reads the literature with the care a clinical reference would receive — not an indicator of clinical practice. ## Editorial method The dossier is built from PubMed-indexed English-language sources where possible — the seminal 2003 Khavinson telomerase paper in *Bulletin of Experimental Biology and Medicine* [1], the 2025 Al-dulaimi independent replication in *Biogerontology* [2], the 2020 Khavinson histone-binding mechanism paper in *Molecules* [3], the Anisimov cancer-model series in *International Journal of Cancer* and *Cancer Letters* [4][5][8], the Korkushko elderly-melatonin cohort work [11][12], the 2002 Khavinson 'Peptides and Ageing' monograph in *Neuro Endocrinology Letters* [14], and the 2025 Araj consolidation review in *International Journal of Molecular Sciences* [15]. Russian-language sources are not cited directly; their contents are referenced via the Khavinson 2002 and Araj 2025 reviews. ## What is honest about this literature The Epitalon literature has unusual geography. Most positive in vivo and cohort data originate from a single research program — the Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology [14]. A large fraction of the supporting work is Russian-language and not well indexed in Western databases. Validated pharmacokinetic data and modern regulatory-grade toxicology packages are absent from the peer-reviewed literature, as the 2025 Araj review explicitly notes [15]. Independent Western replication of the lifespan and cohort-mortality findings is limited. A 2025 cell-line replication has reset the modern reading of the telomerase work [2]. None of this makes the literature worthless — it makes it specific, citable, and bounded. ## What this site does not claim rx Epitalon does not claim Epitalon is safe for human use, effective for any indication, or appropriate for any reader's personal circumstances. It does not endorse the compound. It does not recommend doses. It does not sell, distribute, or refer to any vendor. It does not host advertising for peptide products. The site exists to make the peer-reviewed literature legible to a reader who wants to understand what the published studies actually measured — no more, no less. --- A textile-layered editorial digest of the Khavinson pineal tetrapeptide literature — Epitalon and Epithalon read as one molecule, two spellings, and twenty-five years of mostly-Russian record, with the Western trial gap named. --- # Contact rx Epitalon: Editorial Correspondence on the AEDG Tetrapeptide Dossier > Contact rx Epitalon for editorial correspondence on the AEDG tetrapeptide literature — corrections, additional citations, or sourcing notes. Not a clinic, not a vendor, not a prescribing service. For editorial correspondence on the Epitalon literature — corrections, sourcing notes, additional citations — please use the form below. ## Editorial correspondence only Correspondence to rx Epitalon is for editorial purposes only. The site welcomes notes on citation corrections, additional PubMed-indexed sources we have missed, methodological observations on the literature, and translation or sourcing notes on Russian-language papers that bear on the dossier's accuracy. The site does not respond to inquiries about purchasing peptides, dosing recommendations, personal health decisions, or vendor referrals. We do not consult, prescribe, recommend, or refer. If you are seeking medical advice on any aspect of pineal-axis pharmacology or anti-ageing research, please consult a qualified clinician in your jurisdiction. ## What we do reply to We reply to: editorial corrections (citation errors, mis-attributed findings, broken links); additional citations (PubMed-indexed sources on AEDG, Epithalamin, or the Khavinson program that we have missed); methodological notes on the literature (study design observations, replication-status updates, regulatory-status updates); translation notes (corrections on Russian-to-English transliterations or paper-title fidelity); and inquiries from researchers writing on adjacent compounds in the Khavinson peptide-bioregulator family. ## What we do not reply to We do not reply to: requests for peptide vendors, sources, or purchasing advice; requests for personal dosing recommendations; requests for medical consultations; requests for prescribing referrals; vendor outreach asking for product placement, sponsored content, or affiliate linkage; or marketing inquiries. The site is editorial in intent and structure and has no commercial relationship with any peptide vendor, supplier, manufacturer, or distributor. ## Contact form Please use the form below. Include the page URL you are writing about, the citation number (if applicable), and a brief description of the correction, addition, or note. We read every message; we reply when we have something substantive to add. Replies typically take one to three weeks. --- A textile-layered editorial digest of the Khavinson pineal tetrapeptide literature — Epitalon and Epithalon read as one molecule, two spellings, and twenty-five years of mostly-Russian record, with the Western trial gap named.